Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Makes sense. If Amgen buys us I will invest all of my proceeds into Amgen stock. I will follow the science.
Sorry, that question is above my paygrade. I really hope HOT works well for many patients.
Thanks for posting. Seems more and more that all roads probably lead to NEO in my opinion.
Thanks for recapping the patent info; I believe EU patents have a duration of 20 years from the filing date:
https://en.wikipedia.org/wiki/European_Patent_Convention
We also had favorable ruling in EU when our patents were challenged:
https://www.fiercebiotech.com/biotech/advaxis-prevails-european-patent-court
Like Iggy was implying, many of our patents have been renewed/modified as the science has evolved:
https://patents.justia.com/assignee/advaxis-inc
I think we may have a patent application jointly with Merck for combo of LM and PD1?
I think Catdog posted one time that pharma companies have different rules allegedly about reporting ownership. Not entirely sure?
But isn't NEO going to probably tackle cervical and head and neck cancer?
A Phase 1 Dose-Escalation Study of Advaxis (ADXS) NEO Expressing Personalized Tumor Antigens in Subjects With Metastatic Microsatellite Stable Colon Cancer, Metastatic Squamous Histology Head and Neck Cancer, and Metastatic Non-Small Cell Lung Cancer
Anticipated Study Start Date : March 2018
https://cervicalcancernews.com/2017/06/12/synthetic-genomics-launches-cgmp-suite-for-pharmaceutical-quality-manufacturing-of-synthetic-dna-for-advaxis-clinical-trials/
FBG back in the day it was you and me and handful of posters talking about ADXS on the Yahoo message board. I first invested modestly because of AXAL and the hope someday of PSA; but our constructs continue to evolve, and EVOLVE is the key word why I am investing more now than ever before. I never imagined NEO and HOT back in 2009. I may be insane, but at least I will go down investing in what I believe in.
Good for them, just makes my conviction stronger that we got hosed on our Neo deal.
Wow, special thanks in advance to anyone who goes out into that mess to attend the annual meeting!
Speaking of pitchforks; love Young Frankenstein:
https://video.search.yahoo.com/search/video?fr=skyh&p=young+frankenstein+castle#id=1&vid=651c24b6a63deb27de8382374ba8fb0d&action=click
Jon,
Thanks for the information. Neon Therapeutics is a private company, however I am interested in seeing their progress. I am invested in ADXS, as ultimately I feel that our platform may yield the best results. Time will tell, but the main thing is that we finally conquer cancer.
"LB-150 / 17 - Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform".
It will be interesting to see how this compares to the peptide-based personalized neoantigen vaccines.
Please consider writing an article explaining this.
Agree 100%; and the past month has been a great buying opportunity for those with the moxie. Hoping that we blow through $2.50 on Monday, and ultimately possibly end up with a PBYI type run-up.
How many shares at $19, wasn't it something like 500,000? What do you think their average is?
Been an investor here for almost 9 years; and to my recollection we found out about most past offerings after the fact and they were normally done lower than the existing SP. This one has me worried why it's dragging on with no closure and the SP is stagnant.
Hopefully like we saw in 2015
The Advaxis website seems to be geared towards pediatric regarding HER2. Seems like it may be worth pursuing for a possible priority review voucher for pediatric. Last time I checked I believe 18 year olds we're still considered eligible for pediatric population; not sure how many 18 year olds we may have included in our trial.
Interesting also that we have patent application with division of Merck for LM and PD1 combo I believe.
Did some very rough estimates awhile back on possible EU patent coverage with results of 510 million population total compared to US population of 321 million. Total population estimates.
Agree on that. Personally I am voting to keep Dr. Samir Khleif from Georgia Regents, he is a fairly new member and he has always been a strong supporter of the science in my opinion. But going NO for everyone else.
But why go under 10 percent? Need some astute investor opinions on this?
On Ihub news for ADXS
Agree that this has always been speculative, but it was a hell of a lot more of a risk 9 years ago when I first bought in. With speculative Bio stocks, you have to be pretty damn sure of the science; and do not invest more than you can afford to lose.
I bought last week anticipating that they would submit; hard to predict future price action, but this is an important first step. Plus we have strong patent protection in the EU. Just need to get one approved, and this will pave the way for the other constructs.
Odd thing about my time in China is that I became good friends with a lot of Russian businessmen. Those dudes are bad a$$. Someday I hope to make a trip to Russia.
During my extensive travels through China I never did find a Busch Light; but in Shanghai I did find a PBR tall boy that was made in China. However the local Chinese beers are excellent.
If you do somehow end up in Shanghai, I highly recommend the old French Concession area with the sycamore trees lining the streets. A good place to drink Chinese beer.
Good Luck. Personally I limit myself to under 30% of my 401-K in ADXS; since it is still speculative.
But I have been buying every week over the last 12 months; time will tell if this was a good decision.
Hoping that Merck shows some interest in the company.
Come on Man! Appreciate your posts, but please try to stay above the line.
Agree 100%. I will be buying next week.
Thanks to Gajj for the following:
"February 12, March 8. those are the dates for EMA submission regardless of the type of application or medicine. This from the EMA"
Thanks for checking. Hopefully they met the criteria for possibly being able to submit for the rare pediatric disease voucher for Pediatric Osteosarcoma. Although I am unsure if data from a pediatric population is required?
https://www.cancer.net/cancer-types/osteosarcoma-childhood/statistics
https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM423325.pdf
Thanks Dew, apparently we do not have the priority review voucher; so scratch that off the list as a potential source of income.
http://priorityreviewvoucher.org/
https://www.raps.org/news-articles/news-articles/2017/12/regulatory-explainer-everything-you-need-to-know-about-fda%E2%80%99s-priority-review-vouchers
Just curious; which fast track voucher are you proposing we sell, HER 2 or Axal?
http://ir.advaxis.com/press-release/clinical-data-updates/fda-grants-advaxis-fast-track-designation-adxs-her2-patients
http://ir.advaxis.com/press-release/clinical-data-updates/advaxis-axal-receives-fast-track-designation-fda-adjuvant
Agree 100% that PSA is the wildcard.
Thanks for the feedback. I also did not realize that the FDA is approving genomic profiling tests.
https://www.cancer.gov/news-events/cancer-currents-blog/2017/genomic-profiling-tests-cancer?cid=eb_govdel